This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why Novo Nordisk (NVO) is a Strong Value Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Pharma Stocks Rebound as Trump Announces a 90-Day Pause on Tariffs
by Ekta Bagri
The news of a likely import tariff hurt the share price of pharma giants like Novo Nordisk (NVO), Eli Lilly (LLY) and AstraZeneca (AZN), but Trump's announcement of a pause on reciprocal tariffs offsets the losses.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Zacks Analyst Blog Highlights Procter & Gamble, Novo Nordisk, PepsiCo, Genie Energy and Canterbury Park
by Zacks Equity Research
Procter & Gamble, Novo Nordisk, PepsiCo, Genie Energy and Canterbury Park are included in this Analyst Blog.
Top Analyst Reports for Procter & Gamble, Novo Nordisk & PepsiCo
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including The Procter & Gamble Company (PG), Novo Nordisk A/S (NVO) and PepsiCo, Inc. (PEP), as well as two micro-cap stocks Genie Energy Ltd. (GNE) and Canterbury Park Holding Corporation (CPHC).
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?
by Kinjel Shah
Both LLY and NVO are leading pharmaceutical companies specializing in diabetes and obesity treatments.
Novo Nordisk A/S (NVO) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
NVO & LLY Shares Down on Exclusion of Obesity Drugs From Medicare
by Kinjel Shah
CMS keeps out LLY and NVO's obesity drugs from Medicare coverage. Medicare, at present, does not cover obesity drugs if they are solely prescribed for weight loss.
Novo Nordisk (NVO) Stock Moves -1.67%: What You Should Know
by Zacks Equity Research
Novo Nordisk (NVO) closed at $67.10 in the latest trading session, marking a -1.67% move from the prior day.
LXRX Stock Moves Up 30% in a Week: What is Driving This Rally?
by Zacks Equity Research
The upside comes after Lexicon lands a deal worth $1 billion for its experimental obesity drug with Novo Nordisk.
AbbVie Stock Rises 16% Year to Date: Time to Buy, Sell or Hold?
by Kinjel Shah
Those who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth in 2025.
DXCM Inks Deal With Nanowear to Boost CGM Application Beyond Diabetes
by Zacks Equity Research
DexCom's recent licensing deal with Nanowear is likely to reinforce the broader potential of CGMs in continuous metabolic health monitoring.
Novo Nordisk (NVO) Stock Moves -1.23%: What You Should Know
by Zacks Equity Research
In the latest trading session, Novo Nordisk (NVO) closed at $69.30, marking a -1.23% move from the previous day.
Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.
FDA Expands Exelixis Cabometyx Label for Neuroendocrine Tumors
by Zacks Equity Research
Exelixis obtains FDA nod for label expansion of lead drug Cabometyx for neuroendocrine tumors.
Bayer Licenses PRMT5 inhibitor From Suzhou Puhe BioPharma
by Zacks Equity Research
Bayer obtains an exclusive worldwide license for MTA-cooperative PRMT5 inhibitor from Suzhou Puhe BioPharma for selective targeting of MTAP-deleted tumors.
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
Viking enrolls around 280 participants in the phase II study evaluating the oral version of its obesity drug. Data from this study is expected in 2H25.
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
by Zacks Equity Research
MRK in-licenses an experimental lipoprotein(a) inhibitor from China's Jiangsu Hengrui. This transaction is expected to be closed in the second quarter of 2025.
Bayer Down on Verdict to Pay $2.1B to Plaintiff in Roundup Litigation
by Zacks Equity Research
BAYRY suffers a setback after the jury at the Barnes Roundup trial in the State Court of Cobb County, Georgia, reached a verdict in favor of the plaintiff. Stock declines.
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
by Zacks Equity Research
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
5 Large Drug Stocks to Watch as Industry Recovers
by Kinjel Shah
R&D innovation is likely to remain a major focus area in 2025. In the Large-Cap Pharmaceuticals industry, AbbVie (ABBV), Novo Nordisk (NVO), Novartis (NVS), Pfizer (PFE) and Bayer (BAYRY) are worth retaining in one's portfolio
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
by Ahan Chakraborty
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
5 Low-Leverage Stocks to Buy Amid Trump's Tariff Woes
by Aparajita Dutta
The crux of safe investment lies in choosing a company that is not burdened with debt. You may buy BLFS, WLDN, NXT, NVO and EZPW
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
by Zacks Equity Research
Novo Nordisk (NVO) reachead $78.79 at the closing of the latest trading day, reflecting a -0.27% change compared to its last close.